An integrated science-based approach to drug development

被引:18
作者
Parren, Paul W. H. I. [1 ]
de Winkel, Jan G. J. van [1 ,2 ]
机构
[1] Genmab, NL-3508 AD Utrecht, Netherlands
[2] Univ Med Ctr Utrecht, Dept Immunol, Immunol Lab, Utrecht, Netherlands
关键词
D O I
10.1016/j.coi.2008.06.006
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
引用
收藏
页码:426 / 430
页数:5
相关论文
共 13 条
[1]   Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG fc [J].
Anthony, Robert M. ;
Nimmerjahn, Falk ;
Ashline, David J. ;
Reinhold, Vernon N. ;
Paulson, James C. ;
Ravetch, Jeffrey V. .
SCIENCE, 2008, 320 (5874) :373-376
[2]   Potent antibody therapeutics by design [J].
Carter, PJ .
NATURE REVIEWS IMMUNOLOGY, 2006, 6 (05) :343-357
[3]   Complement-dependent tumor cell lysis triggered by combinations of epidermal growth factor receptor antibodies [J].
Dechant, Michael ;
Weisner, Wencke ;
Berger, Sven ;
Peipp, Matthias ;
Beyer, Thomas ;
Schneider-Merck, Tanja ;
van Bueren, Jeroen J. Lammerts ;
Bleeker, Wim K. ;
Parren, Paul W. H. I. ;
van de Winkel, Jan G. J. ;
Valerius, Thomas .
CANCER RESEARCH, 2008, 68 (13) :4998-5003
[4]   Optimizing engagement of the immune system by anti-timor antibodies: an engineer's perspective [J].
Desjarlais, John R. ;
Lazar, Greg A. ;
Zhukovsky, Eugene A. ;
Chu, Seung Y. .
DRUG DISCOVERY TODAY, 2007, 12 (21-22) :898-910
[5]   Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange [J].
Kolfschoten, Marijn van der Neut ;
Schuurman, Janine ;
Losen, Mario ;
Bleeker, Wim K. ;
Martinez-Martinez, Pilar ;
Vermeulen, Ellen ;
den Bleker, Tamara H. ;
Wiegman, Luus ;
Vink, Tom ;
Aarden, Lucien A. ;
De Baets, Marc H. ;
van De Winkel, Jan G. J. ;
Aalberse, Rob C. ;
Parren, Paul W. H. I. .
SCIENCE, 2007, 317 (5844) :1554-1557
[6]   KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab [J].
Lievre, Astrid ;
Bachet, Jean-Baptiste ;
Boige, Valerie ;
Cayre, Anne ;
Le Corre, Delphine ;
Buc, Emmanuel ;
Ychou, Marc ;
Bouche, Olivier ;
Landi, Bruno ;
Louvet, Christophe ;
Andre, Thierry ;
Bibeau, Frederic ;
Diebold, Marie-Daniele ;
Rougier, Philippe ;
Ducreux, Michel ;
Tomasic, Gorana ;
Emile, Jean-Francois ;
Penault-Llorca, Frederique ;
Laurent-Puig, Pierre .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (03) :374-379
[7]   Structural comparison of fucosylated and nonfucosylated Fc fragments of human immunoglobulin G1 [J].
Matsumiya, Shigeki ;
Yamaguchi, Yoshiki ;
Saito, Jun-ichi ;
Nagano, Mayumi ;
Sasakawa, Hiroaki ;
Otaki, Shizuo ;
Satoh, Mitsuo ;
Shitara, Kenya ;
Kato, Koichi .
JOURNAL OF MOLECULAR BIOLOGY, 2007, 368 (03) :767-779
[8]   Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer [J].
Musolino, Antonino ;
Naldi, Nadia ;
Bortesi, Beatrice ;
Pezzuolo, Debora ;
Capelletti, Marzia ;
Missale, Gabriele ;
Laccabue, Diletta ;
Zerbini, Alessandro ;
Camisa, Roberta ;
Bisagni, Giancarlo ;
Neri, Tauro Maria ;
Ardizzoni, Andrea .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (11) :1789-1796
[9]   Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells [J].
Peipp, Matthias ;
van Bueren, Jeroen J. Lammerts ;
Schneider-Merck, Tanja ;
Bleeker, Wim W. K. ;
Dechant, Michael ;
Beyer, Thomas ;
Repp, Roland ;
van Berkel, Patrick H. C. ;
Vink, Tom ;
van de Winkel, Jan G. J. ;
Parren, Paul W. H. I. ;
Valerius, Thomas .
BLOOD, 2008, 112 (06) :2390-2399
[10]   Isotype selection in antibody engineering [J].
Salfeld, Jochen G. .
NATURE BIOTECHNOLOGY, 2007, 25 (12) :1369-1372